Semax is a synthetic peptide derived from a fragment of the hormone ACTH. It is registered as a medicine in Russia but is not approved by the FDA, EMA, or comparable regulators. This page describes what has been studied, not an established treatment.
Overview
The benefits attributed to Semax fall into two very different categories. The first — faster functional recovery after ischemic stroke and fewer repeat cerebrovascular events in people with diagnosed cerebrovascular insufficiency — is the one with published human trial data behind it, all of it Russian and none of it double-blind. The second — sharper focus, better memory, and resistance to mental fatigue in healthy adults — is the reason most people buy it online, and it has essentially no controlled human evidence at all.
Understanding which category a given claim belongs to is the single most useful filter for reading anything written about this peptide.
What the clinical trials actually measured
Two studies carry most of the weight, both led by Russian neurologists and both published in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova.
Post-stroke rehabilitation, n=110. Gusev and colleagues followed 110 patients after ischemic stroke, split into early and late rehabilitation groups with semax and non-semax subgroups in each. Semax administration raised plasma brain-derived neurotrophic factor regardless of when rehabilitation started, and the combination of semax plus elevated BDNF was associated with faster recovery on the Barthel index — a scale of everyday functional independence. The effect on motor strength was less pronounced (Gusev et al. 2018).
Chronic cerebrovascular insufficiency, n=187. An earlier study assessed 187 patients across stages of cerebrovascular insufficiency using neurological examination, neuropsychological testing, dopplerography, EEG, and MRI. The authors reported clinical improvement, halted disease progression, a lower rate of strokes and transient ischemic attacks, and good tolerability including in elderly patients (Gusev, Skvortsova and Chukanova 2005).
Both are real studies with real patients. Neither describes randomisation or blinding in its published abstract, and both compare subgroups rather than an active arm against a matched placebo. On a rated functional scale like the Barthel index, that design leaves expectancy effects on the table — which matters more, not less, when the reported benefit is modest.
The BDNF thread
The most interesting result in the Semax literature is a biochemical one, because a blood biomarker is harder to influence by expectation than a clinician rating. Semax is an ACTH(4-10) analogue extended with a proline-glycine-proline tail, a modification that slows enzymatic breakdown while removing the parent hormone's corticotropic activity.
Preclinical work supports a specific target. In rat basal forebrain, tritium labelled Semax showed time-dependent, specific, reversible and calcium-dependent binding with a dissociation constant of about 2.4 nM, and intranasal doses of 50 and 250 mcg/kg raised BDNF protein in that region within 3 hours — but not in the cerebellum, indicating a regional rather than global effect (Dolotov et al., J Neurochem 2006). The plasma BDNF rise seen in the 2018 stroke study is the human echo of that line of work.
The honest caveat is that the same stroke study found BDNF also rose with early rehabilitation alone. A neurotrophic marker moving is a mechanism, not a benefit, and the history of medicine is full of biomarkers that moved without outcomes following.
The gap between the trials and the marketing
Nothing above involved a healthy person. The trial populations were stroke survivors and patients with diagnosed cerebrovascular disease — people whose brains had a deficit to recover from. Extrapolating from "helped restore function after an infarct" to "improves concentration during a workday" is a leap the published literature does not make.
Route matters too. The studied exposure is intranasal at defined microgram amounts; research-grade powder sold for subcutaneous injection is a different product with a different absorption profile and no corresponding data. See the Semax dosing page for why that distinction is not a technicality.
Reading a Semax claim
- Ask whether the source is describing a patient population or a healthy one.
- Ask whether the study was blinded. In this literature, the answer is usually no.
- Ask whether the outcome was a biomarker or something a person would notice.
- Ask about route: intranasal solution and injectable powder are not interchangeable.
The fair summary is that Semax is a genuinely researched compound with a plausible neurotrophic mechanism, whose clinical evidence sits one tier below what Western regulators require, and whose consumer-facing claims are extrapolations from stroke medicine rather than findings in their own right. The full picture is in the Semax research and evidence overview.